Well into his study, Rick Strassman had a problem he had not been trained for. He was a careful psychiatrist running a rigorous, government-sanctioned study of a Schedule I drug, measuring blood pressure and cortisol and pupil dilation. But his subjects, minutes after a high intravenous dose of DMT, kept coming back from somewhere and reporting the same impossible thing: they had not merely hallucinated colors and geometry. They had gone somewhere, and in that somewhere, something had been waiting for them. Beings. Intelligences. Entities that seemed to expect them, communicate with them, examine them, and in some cases seemed unsurprised or even annoyed by the human intrusion.
This was not in the protocol. Strassman, a materialist scientist, found himself listening to sober, screened, psychologically healthy volunteers describe encounters that sounded like alien abduction, like contact, like the reports of medieval mystics and shamans across every culture and century. And it kept happening.
The context makes the study extraordinary. Between 1990 and 1995, at the University of New Mexico, Rick Strassman conducted the first new human research on psychedelics in the United States in roughly two decades — the door slammed shut after the backlash of the 1960s had reopened, briefly, for him. It took years of negotiation with the FDA, the DEA, and institutional review boards to win approval. He administered around four hundred doses of DMT — N,N-dimethyltryptamine — to some sixty volunteers, and recorded the results with clinical precision. The book he wrote about it, DMT: The Spirit Molecule (2001), subtitled A Doctor's Revolutionary Research into the Biology of Near-Death and Mystical Experiences, became one of the most influential underground texts of the psychedelic revival, and gave the molecule the name that stuck.
DMT is, chemically, almost absurdly simple — a small tryptamine molecule, structurally close to serotonin, that acts primarily as an agonist at the 5-HT2A serotonin receptor, the same target as psilocybin and LSD.
What sets it apart is its ferocity and its speed. Smoked or injected, DMT produces a total "breakthrough" — a complete replacement of ordinary reality — within seconds, peaking in a couple of minutes and largely over within fifteen. It is the shortest and steepest of all the classic psychedelics, an altered-states|altered state delivered like a slammed door.
And yet it is everywhere. DMT occurs throughout the plant kingdom and, crucially, in the human body and the bodies of other mammals — it is endogenous, a compound our own biology manufactures.
Taken orally it does nothing, because stomach enzymes (monoamine oxidase) destroy it. The peoples of the Amazon solved that problem centuries ago with altered-states|ayahuasca — a brew combining a DMT-bearing plant (Psychotria viridis) with the Banisteriopsis caapi vine, which contains MAO inhibitors that switch off the gut enzymes and let the DMT reach the brain.
That two specific plants out of tens of thousands in the rainforest must be combined to produce an orally active psychedelic is itself one of ethnobotany's genuine mysteries.
The heart of Strassman's data, and its scandal, is the beings. A large fraction of his high-dose volunteers — not a fringe, a substantial share — reported encountering autonomous, intelligent entities in the DMT space: described variously as elves, insects, reptiles, robots, clowns, "beings of light," or presences with no clear form. Terence McKenna, DMT's most eloquent evangelist, had already given them their most famous name — "self-transforming machine elves" — and insisted they were as real as the furniture. What unsettled Strassman was that his controlled, sober subjects, many with no prior interest in the drug, independently reported the same category of experience, often with a striking sense that the entities were more real than everyday reality, not less.
This is the interpretive knife-edge on which the whole subject balances.
Three readings compete, and the drug does not tell you which is right. The first: the entities are hallucinations, the brain's pattern-making machinery running wild under chemical assault, and their cross-cultural similarity reflects shared human neuro-architecture, not shared visitors. The second, more psychological: they are autonomous contents of the unconscious — archetypes, in the Jungian sense — given vivid sensory form. The third, which Strassman himself cautiously entertained and which McKenna embraced: the molecule opens a channel to genuinely independent realities and their inhabitants, and the brain is not a generator but a receiver, briefly retuned. Nothing in the phenomenology settles the question, which is precisely why it will not go away.
Strassman's boldest and most criticized move was to propose a source. The pineal gland — the tiny, single, unpaired structure deep in the brain that pineal-gland|Descartes had called the seat of the soul — was, he speculated, the body's DMT factory: manufacturing the compound and releasing a flood of it at the moments of greatest transition, birth and death, and in the deepest states of meditation and mystical experience.
This is what earned DMT the title "the spirit molecule." If true, it would mean the brain contains a chemical mechanism for transcendence, and that the visions of the dying, the ecstasies of mystics, and the reports of the near-death-experiences|near-death experience all share a single molecular trigger.
The hypothesis is speculative, and Strassman was honest that it was. Critics pointed out that the pineal is tiny and produces DMT, if at all, in quantities far too small to account for a psychedelic dose. But the underlying idea — that DMT is endogenous and biologically active — has only gained ground.
In 2019 a team led by Jimo Borjigin at the University of Michigan reported evidence that the mammalian brain synthesizes DMT, identifying the necessary enzymes not only in the pineal but in the neocortex and hippocampus — and, most provocatively, found that DMT levels rise — roughly two-and-a-half-fold — in the brains of rats undergoing cardiac arrest. The specific pineal claim looks shaky; the deeper intuition — that the dying brain may flood itself with a psychedelic, and that this is what the near-death-experiences|NDE rides on — looks more plausible than when Strassman first floated it.
Strip away the elves and the mysticism and the stakes are the same as everywhere else in the study of mind. If DMT merely scrambles the consciousness|conscious brain, it is a fascinating pharmacological curiosity and nothing more. But if the "receiver" reading has any truth — if the ordinary brain is, as Aldous Huxley proposed in The Doors of Perception (1954), a reducing valve that filters a vast reality down to the trickle needed for survival, and DMT briefly opens the valve — then the drug is a door, and what comes through it is data about a cosmos far larger than Materialism allows.
That is the same fork the near-death-experiences|near-death experience presents, and DMT sharpens it to a chemical point: a single molecule, made by our own cells, that can dissolve the world and populate the dissolution with minds.
For decades this question could not even be asked in a laboratory. That has changed. At Imperial College London, researchers led by Christopher Timmermann have mapped the DMT state with EEG and pushed toward "extended-state" DMT — continuous intravenous infusion that holds a subject in the breakthrough space long enough to explore it, turning a fifteen-minute lightning strike into a sustained expedition.
The therapeutic promise is real; so is the scientific caution. But the deepest reason the research matters is the one Strassman stumbled into in his own laboratory: DMT is the place where the chemistry of the brain and the oldest reports of contact with other worlds meet in a single syringe, and no one yet can say whether what the volunteers met was inside them or on the other side of a door the molecule briefly held open.